Candesartan: profile and news

Kidney Trouble Speeds Heart Failure  Feb 6, 2006
...study finds. Researchers analyzed data on 2,680 North American patients who took part in a study involving the drug candesartan. "We ... - Forbes

Botox shots may help kids who have cerebral palsy  Feb 12, 2006
...finds. Researchers analyzed data on 2,680 North American patients who took part in a study involving the drug candesartan. "Notably ... - Indianapolis Star,

Kidney Trouble Speeds Heart Failure  Feb 6, 2006
...study finds. Researchers analyzed data on 2,680 North American patients who took part in a study involving the drug candesartan. "We ... - Forbes

Music, Healing Touch May Aid Recovery  Jan 16, 2006
New analysis of a major heart failure study demonstrates that patients treated with Atacand (candesartan) to lower blood pressure reported greater improvement ... - Saturday Evening Post,

New Analysis of CHARM Programme Provides Key Insights into Patient ...  Dec 7, 2005
December 7, 2005 -- AstraZeneca today announced that the December 10th issue of The Lancet published results of an analysis of the Candesartan in Heart failure ... - DG News

Faithful Adherence to Placebo Is Predictive of Outcome  Dec 7, 2005
That's the take-home message from the 7,600-patient Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity (CHARM) study in which ... - MedPage Today,

Medication Adherence Linked to Improved Heart Failure Survival  Dec 7, 2005
The findings stem from an analysis of data for 7599 CHF patients enrolled in the Candesartan in Heart failure: Assessment of Reduction in Mortality and ... - Medscape (subscription)

Chronic Heart Failure Patients Who Stick To Their Medication More ...  Dec 9, 2005
CHARM trial Bradi Granger (Duke University Health System, Durham, North Carolina, USA) and colleagues compared the effects of the drug candesartan with placebo ... - Medical News Today (press release),

Govt medicine spending slammed as 'pathetic'  Dec 5, 2005
In addition to these new investment decisions, Pharmac widened access to treatments for patients who had heart failure (candesartan), breast cancer (letrozole ... - Stuff.co.nz,

Medications Keep Heart-Failure Patients Alive  Dec 6, 2005
The patients were assigned to receive the angiotensin receptor blocker candesartan or a placebo, and were followed for three years. ... - Forbes

Anti-depressant prescriptions rising  Dec 5, 2005
In addition to these new investments, Pharmac widened access to treatments for patients who had heart failure (candesartan), breast cancer (letrozole), nausea ... - TVNZ,

Spending on target, patient numbers growing  Dec 5, 2005
In addition to these new investment decisions, PHARMAC widened access to treatments for patients who had heart failure (candesartan), breast cancer (letrozole ... - Scoop.co.nz (press release),

TAKEDA UK LTD RECOGNISED IN PRESTIGIOUS PHARMACEUTICAL INDUSTRY  Dec 7, 2005
...disease - Takeda pioneered the class of angiotensin receptor blockers (ARBs), and markets a product in this class, Amias(R) (candesartan cilexetil), which is ... - ITNews,

AstraZeneca Provides Additional Support to Hurricane Victims  Nov 17, 2005
These medicines include: ACCOLATE® (zafirlukast), ARIMIDEX® (anastrozole), ATACAND® (candesartan cilexetil), ATACAND HCT® (candesartan cilexetil ... - Yahoo! News (press release)

AstraZeneca Provides Additional Support to Hurricane Victims  Nov 17, 2005
These medicines include: ACCOLATE(R) (zafirlukast), ARIMIDEX(R) (anastrozole), ATACAND(R) (candesartan cilexetil), ATACAND HCT(R) (candesartan cilexetil ... - PR Newswire (press release),

Angiotensin Blockade Alone Decreases Albuminuria in Children with ...  Nov 17, 2005
...therapy. The drugs used were enalapril 0.25 to 0.5 mg/kg/day, candesartan 0.2 to 0.4 mg/kg/day and losartan 0.4 to 1 mg/kg/day. ... - DG News

Boost for dual heart failure approach  Oct 18, 2005
Evidence to be included in the guidelines was derived from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program ... - AustralianDoctor.com (subscription),

Risk of heart attack and cardiovascular death significantly ...  Oct 12, 2005
12 /CNW/ - Data published in the Journal of the American Medical Association, JAMA(1) today show that ATACAND(R) (candesartan cilexetil) is the first ... - Canada NewsWire (press release),

New Analysis of CHARM Program Published in JAMA Evaluates Effect ...  Oct 11, 2005
...today announced the October 12 issue of the Journal of the American Medical Association published results of a secondary analysis of the Candesartan in Heart ... - PR Newswire (press release),

AstraZeneca's Atacand cuts heart attack, death risk: study  Oct 12, 2005
LONDON (MarketWatch) -- Data published in the Journal of the American Medical Association Wednesday show that Atacand (candesartan cilexetil) is the first ... - MarketWatch

Risk of Heart Attack and Cardiovascular Death Significantly ...  Oct 11, 2005
MÖLNDAL, SWEDEN -- October 11, 2005 -- Data published in the Journal of the American Medical Association today show that Atacand (candesartan cilexetil) is ... - DG News

Takeda: an East wind blows good for Blopress  Oct 13, 2005
The CHF approvals for candesartan, which AstraZeneca markets under license as Atacand, are based on positive results from an AstraZeneca study program named ... - Pharmaceutical Business Review

Additional Indication of Blopress for the Treatment of Chronic ...  Oct 11, 2005
...of Labor, Health and Welfare (MLHW) in Japan approved on October 11 the use of its angiotensin receptor blocker ("ARB"), BlopressR (candesartan cilexetil) of ... - PharmaLive.com (press release),

Takeda gains approval to sell Bropress as heart failure treatment ...  Oct 11, 2005
...failure, it said. Bropress, known as Candesartan in the US, was originally approved as a hypertension treatment. Sales of Bropress ... - Forbes

Risk of Heart Attack and Cardiovascular Death Significantly ...  11 Oct 2005
MÖLNDAL, SWEDEN -- October 11, 2005 -- Data published in the Journal of the American Medical Association today show that Atacand (candesartan cilexetil) is ... - DG News

Additional Indication of Blopress for the Treatment of Chronic ...  11 Oct 2005
...of Labor, Health and Welfare (MLHW) in Japan approved on October 11 the use of its angiotensin receptor blocker ("ARB"), BlopressR (candesartan cilexetil) of ... - PharmaLive.com (press release),

Takeda gains approval to sell Bropress as heart failure treatment ...  11 Oct 2005
...failure, it said. Bropress, known as Candesartan in the US, was originally approved as a hypertension treatment. Sales of Bropress ... - Forbes

CHARM Program Evaluates Effects of ATACAND(R) (candesartan ...  Sep 6, 2005
6 /PRNewswire-FirstCall/ -- Results were released from a prospectively defined, secondary analysis of the Candesartan in Heart Failure Assessment of Reduction ... - PR Newswire (press release),

(PRN) - Met-Pro Corporation's Systems Division Receives Equipment ...  Sep 6, 2005
...[+]. (PRN) - CHARM Program Evaluates Effects of ATACAND(R) (candesartan cilexetil) on the Development of Diabetes in Patients With Heart Failure ... [+. ... - Bolsamania.com,

AstraZeneca Pledges More Than $1 Million in Contributions and ...  Sep 1, 2005
These medicines include: ACCOLATE(R) (zafirlukast), ARIMIDEX(R) (anastrozole), ATACAND(R) (candesartan cilexetil), ATACAND HCT(R) (candesartan cilexetil ... - PR Newswire (press release),

Strategies to Prevent Type 2 Diabetes  Aug 12, 2005
...and have consistently demonstrated reductions in the risk of new diabetes ranging from 2% to 87% (Table 3). Two of these trials, namely Candesartan in Heart ... - RedNova.com,

Candesartan therapy can reduce the risk of diabetes in heart ...  Jul 10, 2005
A reduction in the risk of developing diabetes has been shown in heart failure patients on candesartan cilexetil ("candesartan") therapy. ... - Medical News Today (press release)

Candesartan Therapy Can Reduce the Risk of Diabetes in Heart ...  Jul 6, 2005
OSAKA, Japan, July 6, 2005, --- A reduction in the risk of developing diabetes has been shown in heart failure patients on candesartan cilexetil ("candesartan ... - PharmaLive.com (press release)

PHARMAC welcomes increased budget for 2006 year  Jul 25, 2005
Access was also widened to medicines including letrozole for breast cancer; candesartan for blood pressure management; olanzapine for mental illness; and ... - Scoop.co.nz (press release)

"Diabesity" and Kidney Function  Jul 19, 2005
Clinically, angiotensin-converting enzyme (ACE) inhibitors (such as lisinopril and ramipril) and angiotensin-receptor blockers (such as candesartan and losartan ... - RedNova.com

No significant drug interactions have been reported in studies of candesartan cilexetil given with other drugs such as glyburide, nifedipine, digoxin, warfarin, hydrochlorothiazide, and oral contraceptives in healthy volunteers, or given with enalapril to patients with heart failure (NYHA class II and III). Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.

Lithiumó Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists. An increase in serum lithium concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.